<DOC>
	<DOCNO>NCT02460393</DOCNO>
	<brief_summary>This study randomize , double-blind placebo-controlled trial healthy subject . There 6 Groups follow : 5mg , 15mg , 30mg , 50mg , 75mg , 100mg , group includes12 people . A single subcutaneous injection administrate start low dose group ( accordance 5mg , 15mg , 30mg , 50mg , 75mg , 100mg administer subcutaneously ) . Pharmacokinetics pharmacodynamics data collect ; drug metabolism pharmacokinetics characteristic analyze . Drug safety tolerance subject evaluate .</brief_summary>
	<brief_title>A Trial With Humanized TNFα Monoclonal Antibody Injection Single Dose Dose Escalation Healthy Subjects</brief_title>
	<detailed_description>This study randomize , double-blind placebo-controlled trial healthy subject . There 6 Groups follow : 5mg , 15mg , 30mg , 50mg , 75mg , 100mg , group includes12 people . A single subcutaneous injection administrate start low dose group ( accordance 5mg , 15mg , 30mg , 50mg , 75mg , 100mg administer subcutaneously ) . Pharmacokinetics pharmacodynamics data collect ; drug metabolism pharmacokinetics characteristic analyze . Drug safety tolerance subject evaluate . The study observe blood concentration experimental drug different time point administration , TNFα treatment different time point observe well . C-T curve drawn blood drug concentration ( c ) time ( T ) trial . At time , investigator draw average plasma concentration curve . Compartmental non compartmental model use analyze pharmacokinetic parameter subject . It judge linear nonlinear elimination correlation analysis AUC , Cmax different dos . In meantime , adverse event , vital sign , physical examination , laboratory examination ECG evaluate .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1. healthy adult volunteer voluntary participate clinical trial , sign inform consent 2. aged 1845 year , batch subject age difference less equal 10 year age 3. subject qualified physical examination within 7 day trial , body mass index ( BMI ) from19 24 , batch subject similar weight 4. basic indicator heart , liver , kidney blood examination normal range . 1. subject acute chronic infection period , previous history active tuberculosis 2. subject history diseases central nervous system , cardiovascular system , kidney , liver ( specific index liver function ) , digestive system , respiratory system metabolic system suffer significant disease 3. subject allergic constitution inquiry , suspect confirmed history drug , food allergy , subject clear history allergy / allergic humanize TNF alpha monoclonal antibody ingredient humanize TNF alpha monoclonal antibody , serum immunoglobulin E ( IgE ) examination abnormal 4. subject include clinical trial drug 3 month enrol clinical trial , candidate use drug know damage main organ within 3 month trial ; 5. candidate blood donation history 3 month enrol 6 . Prescription non prescription drug administrate Within 2 week inclusion 7 . ALT AST &gt; 1.5N ( upper limit normal ) , Cr &gt; N ( upper limit normal ) ; 8. leukocyte absolute value le 3.50 × 109/L &gt; 9.50× 109/L , neutrophil absolute value le 1.8× 109/L , platelet count less 100 × 109/L , hemoglobin le 100g/L 9. hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody ( HCVAb ) , acquire immunodeficiency syndrome ( AntiHIV ) antibody anti Treponema pallidum antibody ( TPAb ) positive subject 10. candidate positive tuberculin skin test 5 unit dose tuberculin , size 4872 hour scleroma great 5 mm 11. subject positive anti nuclear antibody ( ANA , dsDNA , ENA ) 12. subject positive resistantance antibody 13. subject history mental illness 14. subject pregnant , lactating woman plan pregnant within 3 month 15. subject history orthostatic hypotension 16. drug drug abuse history inquiry 17. daily smoke 5 cigarette amount tobacco inquiry 18. subject drink 28 unit alcohol inquiry , alcohol breath test positive within 24 hour acceptance test drug 19 . There family history cancer 20 . Significantly abnormal value clinical appear screen 21. subject understand , exchangeand cooperate enough , guarantee researcher accord scheme 22. researcher n't think right participate research reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>tolerance</keyword>
	<keyword>safety pharmacokinetic characteristic</keyword>
</DOC>